Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Moupali Das et al.|New England Journal of Medicine|2024Cited by 471
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studySufia Dadabhai, Jia Jin Kee, Mubiana Inambao et al.|UNC Libraries|2025Cited by 0
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIVVimla Naicker, Nonhlanhla N. Mkhize, Peter B. Gilbert et al.|UNC Libraries|2025Cited by 0